Home / Centerstage / 2014 / may / Week 2 /
AstraZeneca rejects Pfizer's "final" offer of £55 per share, amounting to approximately £70 billion. This rejection challenges Pfizer's ambition to create the world's largest pharmaceutical company through a merger. AstraZeneca's decision comes shortly after Pfizer's ultimatum, signaling the company's determination to remain independent and raising questions about the future of the potential deal.
Sunday, 18 May, 2014